Impact of Neoadjuvant Chemotherapy on Locoregional Surgical Treatment of Breast Cancer

2015 ◽  
Vol 22 (5) ◽  
pp. 1425-1433 ◽  
Author(s):  
Eleftherios P. Mamounas
Keyword(s):  
Breast Cancer ◽  
Surgical Treatment ◽  
Neoadjuvant Chemotherapy

scholarly journals The Neutrophil–Lymphocyte Ratio has Little Impact on Survival in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy Followed by Surgery

2021 ◽  
Author(s):  
Katsuhisa Enomoto ◽  
Satsuki Fukumoto ◽  
Hironori Goto ◽  
Satoshi Mori ◽  
Yukiko Hara ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Surgical Treatment ◽  
Neoadjuvant Chemotherapy ◽  
Cancer Patients ◽  
Early Stage ◽  
Disease Free Survival ◽  
Breast Cancer Patients ◽  
Free Survival ◽  
Neutrophil Lymphocyte Ratio ◽  
Disease Free

Abstract Background: The impact of the neutrophil–lymphocyte ratio (NLR) on the survival outcomes of patients with early-stage breast cancer is controversial. Methods: We reviewed a series of 115 breast cancer patients who received neoadjuvant chemotherapy followed by surgical treatment. The NLR was calculated using a blood sample obtained before neoadjuvant chemotherapy. The relationships of disease-free survival with the NLR as well as other clinicopathological factors were assessed.Results: There was no significant association between the NLR and disease-free survival in these patients. On the other hand, negative estrogen receptor and progesterone receptor statuses, extended nodal involvement, and advanced TNM stage were significant predictors of shorter disease-free survival.Conclusions: The NLR has little impact on the survival of early-stage breast cancer patients treated with neoadjuvant chemotherapy followed by surgical treatment.

scholarly journals A Review and Current Update on Sentinel Lymph Node Biopsy of Breast Cancer

2020 ◽  
Vol 8 (F) ◽  
pp. 78-83
Author(s):  
Stacia Novia Marta ◽  
Nyoman Dwi Aussi Hary Mastika ◽  
Hendry Irawan
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Surgical Treatment ◽  
Sentinel Lymph Node ◽  
Sentinel Lymph Node Biopsy ◽  
Neoadjuvant Chemotherapy ◽  
Lymphatic Mapping ◽  
Early Cancer ◽  
Lymph Node Biopsy ◽  
Node Biopsy

Sentinel lymph node biopsy (SLNB) has become the standard staging technique in the surgical treatment of breast cancer, replacing the older method of dissecting lymph nodes of the axilla. Several advantages like lowering of the morbidities that accompany the technique and being less invasive have given rise to a promising effect on life aspects of patients suffering from this morbidity. The procedure has evolved over the last few decades, but further studies are still needed to make improvements. Several aspects of the evolution of SLNB, such as the incorporation of the management in early cancer, the technique of lymphatic mapping, the accuracy of the technique, and its utility and evaluation in clinical response after neoadjuvant chemotherapy are discussed in this review.  

MRI-Model to Guide the Surgical Treatment in Breast Cancer Patients After Neoadjuvant Chemotherapy

2010 ◽  
Vol 251 (4) ◽  
pp. 701-707 ◽  
Author(s):  
Marieke E. Straver ◽  
Claudette E. Loo ◽  
Emiel J. T. Rutgers ◽  
Hester S. A. Oldenburg ◽  
Jelle Wesseling ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Surgical Treatment ◽  
Neoadjuvant Chemotherapy ◽  
Cancer Patients ◽  
Breast Cancer Patients

Effect of Neoadjuvant Chemotherapy on the Surgical Treatment of Patients With Locally Advanced Breast Cancer Requiring Initial Mastectomy

2015 ◽  
Vol 15 (5) ◽  
pp. e231-e235 ◽  
Author(s):  
Emmanuel Barranger ◽  
Julie Antomarchi ◽  
Emmanuel Chamorey ◽  
Constance Cavrot ◽  
Bernard Flipo ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Surgical Treatment ◽  
Neoadjuvant Chemotherapy ◽  
Advanced Breast Cancer ◽  
Locally Advanced Breast Cancer ◽  
Locally Advanced ◽  
Advanced Breast

Neoadjuvant therapy and rates of margin re-excision in patients with invasive breast cancer.

2011 ◽  
Vol 29 (27_suppl) ◽  
pp. 131-131
Author(s):  
E. M. Hanna ◽  
S. Musunuru ◽  
T. Flippo-Morton ◽  
T. Sarantou ◽  
H. J. Norton ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Surgical Treatment ◽  
Neoadjuvant Chemotherapy ◽  
Invasive Breast Cancer ◽  
Neoadjuvant Treatment ◽  
Breast Conservation ◽  
Breast Conservation Therapy ◽  
Primary Treatment ◽  
Partial Mastectomy ◽  
Breast Cancer Patients

131 Background: Many patients with invasive breast cancer receive neoadjuvant chemotherapy (NACT) prior to undergoing definitive surgical management in an effort to facilitate breast conservation. This study compares the re-excision rates of patients undergoing NACT with those who proceed directly to surgical treatment. A retrospective review of all breast cancer patients treated with neoadjuvant chemotherapy between November 2007 and June 2010 was performed. Re-excision rates were calculated for patients who received NACT and were then compared to a group of contemporaneous patients who did not receive neoadjuvant treatment (non-NACT). Re-excisions were routinely performed for disease <2mm from the margin. Patients with DCIS or LCIS were excluded. For statistical analysis, t-test and chi square tests were performed using SAS v9.2. Results: During the study period, 152 patients received neoadjuvant chemotherapy and then underwent surgical treatment of breast cancer. Of these patients, 108 (71.0%) underwent partial mastectomy as primary treatment, 44 (29.0%) underwent mastectomy. As a comparison group, we evaluated 188 consecutive patients diagnosed with invasive breast cancer who underwent initial treatment in the form of partial mastectomy. Table 1 demonstrates the characteristics of NACT and non-NACT patients and margin re-excision rates. Conclusions: Neoadjuvant chemotherapy is often administered in an effort to allow women with larger tumors to pursue breast conservation therapy. This study demonstrates that the rate of margin re-excision in NACT patients is not statistically different from those patients who undergo partial mastectomy as their primary treatment. [Table: see text]

Sign in / Sign up

Export Citation Format

Share Document